Search research articles
Contact Us
Filters
Showing results (1-10 of 98) with videos related to
Page
of 10
Sort By:
Expert Review of Clinical Pharmacology
|
January 14, 2014
Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications
Gerhard Rammes
International Journal of Molecular Sciences
|
December 9, 2023
Molecular Mechanism of Alzheimer's Disease
Gerhard Rammes
Expert Opinion on Drug Discovery
|
March 27, 2019
GABA(A) receptor-targeted drug development -New perspectives in perioperative anesthesia
Bernd Antkowiak, Gerhard Rammes
Idrugs : the Investigational Drugs Journal
|
March 9, 2006
Neramexane (merz pharmaceuticals/forest laboratories)
Gerhard Rammes, Anja Schierloh
Molecular Neurobiology
|
October 6, 2007
Modulation of ligand-gated ion channels by antidepressants and antipsychotics
Gerhard Rammes, Rainer Rupprecht
Expert Opinion on Investigational Drugs
|
April 1, 2017
Preclinical to phase II amyloid beta (A<sub>β</sub>) peptide modulators under investigation for Alzheimer's disease
Chris G Parsons, Gerhard Rammes
Neuropharmacology
|
August 8, 2020
The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ<sub>1-42</sub> on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ<sub>1-42</sub>, suggesting a beneficial prion-like seeding mechanism
Gerhard Rammes, Chris G Parsons
Current Opinion in Anaesthesiology
|
March 15, 2006
Cannabinoids in anaesthesia and pain therapy
Shahnaz Christina Azad, Gerhard Rammes
Current Topics in Medicinal Chemistry
|
December 30, 2011
Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO)
Caroline Nothdurfter, Rainer Rupprecht, Gerhard Rammes
Journal of Alzheimer'S Disease : JAD
|
September 23, 2010
Anesthetics promoting in vitro AβPP metabolism and amyloid-β toxicity
Barbara Eckel, Manfred Blobner, Gerhard Rammes
Page
of 10
Search research articles
Search
Showing results (1-10 of 98) with videos related to
Sort By:
Page
of 10
Expert Review of Clinical Pharmacology
|
January 14, 2014
Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications
Gerhard Rammes
International Journal of Molecular Sciences
|
December 9, 2023
Molecular Mechanism of Alzheimer's Disease
Gerhard Rammes
Expert Opinion on Drug Discovery
|
March 27, 2019
GABA(A) receptor-targeted drug development -New perspectives in perioperative anesthesia
Bernd Antkowiak, Gerhard Rammes
Idrugs : the Investigational Drugs Journal
|
March 9, 2006
Neramexane (merz pharmaceuticals/forest laboratories)
Gerhard Rammes, Anja Schierloh
Molecular Neurobiology
|
October 6, 2007
Modulation of ligand-gated ion channels by antidepressants and antipsychotics
Gerhard Rammes, Rainer Rupprecht
Expert Opinion on Investigational Drugs
|
April 1, 2017
Preclinical to phase II amyloid beta (A<sub>β</sub>) peptide modulators under investigation for Alzheimer's disease
Chris G Parsons, Gerhard Rammes
Neuropharmacology
|
August 8, 2020
The Aβ aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of Aβ<sub>1-42</sub> on LTP even following serial dilution to a 500:1 stoichiometric excess of Aβ<sub>1-42</sub>, suggesting a beneficial prion-like seeding mechanism
Gerhard Rammes, Chris G Parsons
Current Opinion in Anaesthesiology
|
March 15, 2006
Cannabinoids in anaesthesia and pain therapy
Shahnaz Christina Azad, Gerhard Rammes
Current Topics in Medicinal Chemistry
|
December 30, 2011
Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO)
Caroline Nothdurfter, Rainer Rupprecht, Gerhard Rammes
Journal of Alzheimer'S Disease : JAD
|
September 23, 2010
Anesthetics promoting in vitro AβPP metabolism and amyloid-β toxicity
Barbara Eckel, Manfred Blobner, Gerhard Rammes
Page
of 10